Cat. #161897
TOV-2223G
Cat. #: 161897
Availability: 8-10 weeks
Organism: Human
Tissue: Ovary
Disease: Cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de L’université de Montréal
Primary Citation: Ouellet, et al. 2008. BMC Cancer 28,8:(152). PMID 18507860
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: TOV-2223G
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Tissue: Ovary
- Donor: Donor was 89 at diagnosis with Stage 3, IIIC ovarian high-grade serous adenocarcinoma. Patient had undergone some pre-treatment prior to speciment collection in 2004. There is also a TP53 Exon 4 mutation
- Disease: Cancer
- Morphology: Large cells with cobblestone morphology
- Growth properties: Mixed
- Crispr: No
- Description: Epithelial ovarian cancer cell line derived from poorly differentiated serous solid tumors.
- Production details: Tumor was macro-dissected onto 100mm petri dish with serum-free OSE medium supplemented with 1000 U of collagenase. Cells were resuspended after several hours into 8ml of medium, divided into four separate 60mm petri dishes and 10% FBS was added
- Biosafety level: 1
Handling
- Format: Frozen
- Growth medium: Serum free OSE medium
- Temperature: 37° C
- Atmosphere: 5% CO2 and 5% O2
- Shipping conditions: Dry Ice
- Storage conditions: Liquid Nitrogen
- Cultured in antibiotics: 2.5ug/ml amphotericin B and 50 ug/ml gentamicin
- Characterisation tests: Immunohistochemistry, Cytogenetics/Spectral Karyotyping, Single-stran conformation polymorphism analysis, etc.
- Str profiling: TH01: 6,9 / D21S11: 30,31 / D5S818: 12 / D13S317: 11 / D7S820: 12 / D16S539: 10,15 / CSF1PO: 12 / vWA: 17,19 / TPOX: 11 / AMEL: X
References
- Linh, et al. 2023. Future Sci OA. 29, 9(8):FSO875. PMID: 37621847
- Sauriol, et al. 2023. Sci Rep. 27, 13(1):3334. PMID: 36849518
- Sevinyan, et al. 2022. Cancers (Basel). 16, 14(22):5628. PMID:36428724
- Ouellet, et al. 2008. BMC Cancer 28,8:(152). PMID 18507860
